

Professor Marco Gerlinger



95-97 Harley Street
London, W1G 6AF
T +44 (0) 20 7317 2500
www.theloc.com

Jennifer Hills
E. gerlingerpa@hcahealthcare.co.uk
T. 0207 317 2562

5 April 2024

AXA PPP Healthcare
PPP House
Crescent Road
Tunbridge
Via email: cancercareteam@axahealth.co.uk

Dear AXA,

Re: Name: Mr Jialin Yang
DOB: 6/03/1985 Insurance Policy: 7086947S
LOC Number: LOC073298 X Number: X3077596 NHS Number: 7178871857
Add.: Flat 48 Cornwell House 13 Ron Leighton Way E6 1EQ
Email: zakkyang@hotmail.com Mobile Phone: 07856226910

Malignant neoplasm of sigmoid colon

Mr Jialin Yang (DOB 06/03/1985) is a young patient under my care for the treatment of a metastatic colon cancer. We just received RAS and BRAF mutation test results which show the tumour is wild type for these genes. Funding for the addition of cetuximab to the FOLFIRI chemotherapy has already been requested. The tumour is also mismatch repair proficient. I would be grateful if you could authorise funding for genomic analysis of his tumour with the FoundationOne CDx test. This is particularly relevant in young patients who have a higher prevalence of POLE/POLD mutant cancers that can benefit from immunotherapy and to assess the possibility of high tumour mutation burden which may also qualify him for immunotherapy. Furthermore, HER2 amplifications are enriched in RAS/BRAF wild type tumours. It would open additional therapeutic options beyond first line therapy if a HER2 amplification is detected.

Yours sincerely,

A handwritten signature in dark blue ink, appearing to read 'M Gerlinger', is written over a light blue horizontal line.

Professor Marco Gerlinger

cc: Jialin Yang via email